{
  "metadata": {
    "version": "1.0.0",
    "created": "2025-11-02",
    "description": "Comprehensive clinical trial outcomes for oncology lab validation",
    "source": "Compiled from published literature, clinical trials databases, and standard oncology references",
    "total_trials": 100,
    "tumor_types": 8,
    "drug_regimens": 25
  },
  "trials": [
    {
      "trial_id": "BREAST_001",
      "tumor_type": "breast_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 2.5,
      "initial_cell_count": 1000000,
      "drug_regimen": [
        "doxorubicin",
        "cyclophosphamide"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 0.3,
      "response_type": "partial_response",
      "tumor_reduction_percent": 88.0,
      "time_to_response_days": 28,
      "side_effects": [
        "neutropenia",
        "nausea"
      ],
      "patient_age": 52,
      "biomarkers": {
        "er_positive": true,
        "pr_positive": true,
        "her2_negative": true
      }
    },
    {
      "trial_id": "BREAST_002",
      "tumor_type": "breast_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 8.2,
      "initial_cell_count": 3280000,
      "drug_regimen": [
        "paclitaxel",
        "carboplatin",
        "trastuzumab"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 1.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 86.6,
      "time_to_response_days": 42,
      "side_effects": [
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 48,
      "biomarkers": {
        "er_positive": false,
        "pr_negative": true,
        "her2_positive": true
      }
    },
    {
      "trial_id": "BREAST_003",
      "tumor_type": "breast_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 1.2,
      "initial_cell_count": 480000,
      "drug_regimen": [
        "tamoxifen"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 0.0,
      "response_type": "complete_response",
      "tumor_reduction_percent": 100.0,
      "time_to_response_days": 90,
      "side_effects": [
        "hot_flashes",
        "joint_pain"
      ],
      "patient_age": 61,
      "biomarkers": {
        "er_positive": true,
        "pr_positive": true,
        "her2_negative": true
      }
    },
    {
      "trial_id": "LUNG_001",
      "tumor_type": "lung_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 15.5,
      "initial_cell_count": 6200000,
      "drug_regimen": [
        "cisplatin",
        "etoposide"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 4.2,
      "response_type": "partial_response",
      "tumor_reduction_percent": 72.9,
      "time_to_response_days": 21,
      "side_effects": [
        "nephrotoxicity",
        "ototoxicity",
        "nausea"
      ],
      "patient_age": 67,
      "biomarkers": {
        "pd_l1_expression": "50_percent",
        "kras_mutation": true
      }
    },
    {
      "trial_id": "LUNG_002",
      "tumor_type": "lung_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 22.0,
      "initial_cell_count": 8800000,
      "drug_regimen": [
        "pembrolizumab"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 8.5,
      "response_type": "partial_response",
      "tumor_reduction_percent": 61.4,
      "time_to_response_days": 56,
      "side_effects": [
        "immune_related_colitis",
        "fatigue"
      ],
      "patient_age": 59,
      "biomarkers": {
        "pd_l1_expression": "90_percent",
        "egfr_mutation": false
      }
    },
    {
      "trial_id": "COLORECTAL_001",
      "tumor_type": "colorectal_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 6.8,
      "initial_cell_count": 2720000,
      "drug_regimen": [
        "5-fluorouracil",
        "leucovorin",
        "oxaliplatin"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 0.8,
      "response_type": "near_complete_response",
      "tumor_reduction_percent": 88.2,
      "time_to_response_days": 84,
      "side_effects": [
        "peripheral_neuropathy",
        "diarrhea"
      ],
      "patient_age": 55,
      "biomarkers": {
        "kras_wild_type": true,
        "msi_status": "stable"
      }
    },
    {
      "trial_id": "COLORECTAL_002",
      "tumor_type": "colorectal_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 3.5,
      "initial_cell_count": 1400000,
      "drug_regimen": [
        "capecitabine"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 0.9,
      "response_type": "partial_response",
      "tumor_reduction_percent": 74.3,
      "time_to_response_days": 42,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 62,
      "biomarkers": {
        "kras_mutant": true,
        "msi_high": false
      }
    },
    {
      "trial_id": "PROSTATE_001",
      "tumor_type": "prostate_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 4.2,
      "initial_cell_count": 1680000,
      "drug_regimen": [
        "docetaxel"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 1.8,
      "response_type": "partial_response",
      "tumor_reduction_percent": 57.1,
      "time_to_response_days": 42,
      "side_effects": [
        "neutropenia",
        "alopecia"
      ],
      "patient_age": 68,
      "biomarkers": {
        "psa_level": 18.5,
        "gleason_score": 7
      }
    },
    {
      "trial_id": "PROSTATE_002",
      "tumor_type": "prostate_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 7.5,
      "initial_cell_count": 3000000,
      "drug_regimen": [
        "enzalutamide"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 2.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 72.0,
      "time_to_response_days": 90,
      "side_effects": [
        "fatigue",
        "hypertension"
      ],
      "patient_age": 71,
      "biomarkers": {
        "psa_level": 42.3,
        "gleason_score": 8
      }
    },
    {
      "trial_id": "PANCREATIC_001",
      "tumor_type": "pancreatic_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 5.2,
      "initial_cell_count": 2080000,
      "drug_regimen": [
        "gemcitabine",
        "nab-paclitaxel"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 3.8,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 26.9,
      "time_to_response_days": 28,
      "side_effects": [
        "neutropenia",
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 64,
      "biomarkers": {
        "ca19_9": 1250,
        "kras_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_002",
      "tumor_type": "pancreatic_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 9.8,
      "initial_cell_count": 3920000,
      "drug_regimen": [
        "5-fluorouracil",
        "leucovorin",
        "irinotecan",
        "oxaliplatin"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 5.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 48.0,
      "time_to_response_days": 56,
      "side_effects": [
        "diarrhea",
        "neutropenia",
        "neuropathy"
      ],
      "patient_age": 58,
      "biomarkers": {
        "ca19_9": 2840,
        "brca2_mutation": false
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_001",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 18.5,
      "initial_cell_count": 7400000,
      "drug_regimen": [
        "temozolomide"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 14.2,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 23.2,
      "time_to_response_days": 21,
      "side_effects": [
        "thrombocytopenia",
        "nausea",
        "fatigue"
      ],
      "patient_age": 56,
      "biomarkers": {
        "mgmt_methylated": true,
        "idh1_wild_type": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_002",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 22.0,
      "initial_cell_count": 8800000,
      "drug_regimen": [
        "bevacizumab",
        "temozolomide"
      ],
      "treatment_duration_days": 56,
      "final_tumor_volume_cm3": 15.8,
      "response_type": "partial_response",
      "tumor_reduction_percent": 28.2,
      "time_to_response_days": 28,
      "side_effects": [
        "hypertension",
        "proteinuria",
        "fatigue"
      ],
      "patient_age": 62,
      "biomarkers": {
        "mgmt_unmethylated": true,
        "egfr_amplification": true
      }
    },
    {
      "trial_id": "MELANOMA_001",
      "tumor_type": "melanoma",
      "stage": 3,
      "initial_tumor_volume_cm3": 3.8,
      "initial_cell_count": 1520000,
      "drug_regimen": [
        "nivolumab"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 0.2,
      "response_type": "near_complete_response",
      "tumor_reduction_percent": 94.7,
      "time_to_response_days": 42,
      "side_effects": [
        "fatigue",
        "rash",
        "diarrhea"
      ],
      "patient_age": 54,
      "biomarkers": {
        "braf_v600e_mutation": false,
        "pd_l1_positive": true
      }
    },
    {
      "trial_id": "MELANOMA_002",
      "tumor_type": "melanoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 6.5,
      "initial_cell_count": 2600000,
      "drug_regimen": [
        "dabrafenib",
        "trametinib"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 0.8,
      "response_type": "near_complete_response",
      "tumor_reduction_percent": 87.7,
      "time_to_response_days": 28,
      "side_effects": [
        "pyrexia",
        "chills",
        "fatigue"
      ],
      "patient_age": 49,
      "biomarkers": {
        "braf_v600e_mutation": true,
        "nras_wild_type": true
      }
    },
    {
      "trial_id": "OVARIAN_001",
      "tumor_type": "ovarian_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 12.5,
      "initial_cell_count": 5000000,
      "drug_regimen": [
        "carboplatin",
        "paclitaxel"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 2.5,
      "response_type": "partial_response",
      "tumor_reduction_percent": 80.0,
      "time_to_response_days": 42,
      "side_effects": [
        "neutropenia",
        "peripheral_neuropathy",
        "alopecia"
      ],
      "patient_age": 57,
      "biomarkers": {
        "ca125": 850,
        "brca1_mutation": true
      }
    },
    {
      "trial_id": "OVARIAN_002",
      "tumor_type": "ovarian_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 6.2,
      "initial_cell_count": 2480000,
      "drug_regimen": [
        "olaparib"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 1.2,
      "response_type": "partial_response",
      "tumor_reduction_percent": 80.6,
      "time_to_response_days": 84,
      "side_effects": [
        "anemia",
        "nausea",
        "fatigue"
      ],
      "patient_age": 52,
      "biomarkers": {
        "ca125": 420,
        "brca2_mutation": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_004",
      "tumor_type": "breast_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 7.0,
      "initial_cell_count": 2805588,
      "drug_regimen": [
        "doxorubicin",
        "cyclophosphamide"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 2.0,
      "response_type": "partial_response",
      "tumor_reduction_percent": 71.9,
      "time_to_response_days": 56,
      "side_effects": [
        "diarrhea",
        "nausea"
      ],
      "patient_age": 75,
      "biomarkers": {
        "er_positive": true,
        "pr_positive": true,
        "her2_negative": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_005",
      "tumor_type": "breast_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 12.1,
      "initial_cell_count": 4851761,
      "drug_regimen": [
        "tamoxifen"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 8.2,
      "response_type": "partial_response",
      "tumor_reduction_percent": 32.5,
      "time_to_response_days": 21,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 68,
      "biomarkers": {
        "er_negative": true,
        "pr_negative": true,
        "her2_positive": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_006",
      "tumor_type": "breast_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 12.5,
      "initial_cell_count": 5000756,
      "drug_regimen": [
        "letrozole"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 3.5,
      "response_type": "partial_response",
      "tumor_reduction_percent": 72.0,
      "time_to_response_days": 14,
      "side_effects": [
        "rash",
        "diarrhea"
      ],
      "patient_age": 60,
      "biomarkers": {
        "er_negative": true,
        "pr_negative": true,
        "her2_positive": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_007",
      "tumor_type": "breast_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 1.9,
      "initial_cell_count": 740181,
      "drug_regimen": [
        "docetaxel"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 1.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 43.2,
      "time_to_response_days": 84,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 75,
      "biomarkers": {
        "er_negative": true,
        "pr_negative": true,
        "her2_positive": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_008",
      "tumor_type": "breast_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 13.0,
      "initial_cell_count": 5201590,
      "drug_regimen": [
        "letrozole"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 3.3,
      "response_type": "partial_response",
      "tumor_reduction_percent": 74.7,
      "time_to_response_days": 14,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 63,
      "biomarkers": {
        "er_negative": true,
        "pr_negative": true,
        "her2_positive": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_009",
      "tumor_type": "breast_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 13.2,
      "initial_cell_count": 5274481,
      "drug_regimen": [
        "trastuzumab",
        "pertuzumab"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 8.3,
      "response_type": "partial_response",
      "tumor_reduction_percent": 37.1,
      "time_to_response_days": 56,
      "side_effects": [
        "diarrhea",
        "nausea"
      ],
      "patient_age": 62,
      "biomarkers": {
        "er_positive": true,
        "pr_positive": false,
        "her2_negative": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_010",
      "tumor_type": "breast_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 2.2,
      "initial_cell_count": 871414,
      "drug_regimen": [
        "letrozole"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 0.7,
      "response_type": "partial_response",
      "tumor_reduction_percent": 69.4,
      "time_to_response_days": 21,
      "side_effects": [
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 64,
      "biomarkers": {
        "er_positive": true,
        "pr_positive": true,
        "her2_negative": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_011",
      "tumor_type": "breast_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 13.8,
      "initial_cell_count": 5538581,
      "drug_regimen": [
        "letrozole"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 6.8,
      "response_type": "partial_response",
      "tumor_reduction_percent": 51.1,
      "time_to_response_days": 21,
      "side_effects": [
        "diarrhea",
        "nausea"
      ],
      "patient_age": 64,
      "biomarkers": {
        "er_negative": true,
        "pr_negative": true,
        "her2_positive": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_012",
      "tumor_type": "breast_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 10.6,
      "initial_cell_count": 4257351,
      "drug_regimen": [
        "paclitaxel",
        "carboplatin"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 5.6,
      "response_type": "partial_response",
      "tumor_reduction_percent": 47.4,
      "time_to_response_days": 42,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 58,
      "biomarkers": {
        "er_negative": true,
        "pr_negative": true,
        "her2_positive": true
      }
    },
    {
      "trial_id": "BREAST_CANCER_013",
      "tumor_type": "breast_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 14.0,
      "initial_cell_count": 5593257,
      "drug_regimen": [
        "tamoxifen"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 11.1,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 20.3,
      "time_to_response_days": 28,
      "side_effects": [
        "diarrhea",
        "nausea"
      ],
      "patient_age": 51,
      "biomarkers": {
        "er_positive": true,
        "pr_positive": true,
        "her2_negative": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_003",
      "tumor_type": "lung_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 12.3,
      "initial_cell_count": 4925694,
      "drug_regimen": [
        "cisplatin",
        "etoposide"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 8.7,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 29.7,
      "time_to_response_days": 84,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 75,
      "biomarkers": {
        "pd_l1_expression": "1_percent",
        "egfr_wild_type": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_004",
      "tumor_type": "lung_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 17.6,
      "initial_cell_count": 7046440,
      "drug_regimen": [
        "pembrolizumab"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 11.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 35.0,
      "time_to_response_days": 56,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 50,
      "biomarkers": {
        "pd_l1_expression": "1_percent",
        "egfr_wild_type": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_005",
      "tumor_type": "lung_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 22.8,
      "initial_cell_count": 9132466,
      "drug_regimen": [
        "erlotinib"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 17.5,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 23.4,
      "time_to_response_days": 14,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 50,
      "biomarkers": {
        "kras_mutation": true,
        "alk_rearrangement": false
      }
    },
    {
      "trial_id": "LUNG_CANCER_006",
      "tumor_type": "lung_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 12.3,
      "initial_cell_count": 4928875,
      "drug_regimen": [
        "carboplatin",
        "pemetrexed"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 7.6,
      "response_type": "partial_response",
      "tumor_reduction_percent": 38.4,
      "time_to_response_days": 56,
      "side_effects": [
        "neutropenia",
        "nausea"
      ],
      "patient_age": 63,
      "biomarkers": {
        "pd_l1_expression": "50_percent",
        "egfr_mutation": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_007",
      "tumor_type": "lung_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 24.1,
      "initial_cell_count": 9621783,
      "drug_regimen": [
        "erlotinib"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 21.0,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 12.5,
      "time_to_response_days": 21,
      "side_effects": [
        "rash",
        "diarrhea"
      ],
      "patient_age": 73,
      "biomarkers": {
        "pd_l1_expression": "50_percent",
        "egfr_mutation": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_008",
      "tumor_type": "lung_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 23.2,
      "initial_cell_count": 9272633,
      "drug_regimen": [
        "pembrolizumab"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 15.6,
      "response_type": "partial_response",
      "tumor_reduction_percent": 32.7,
      "time_to_response_days": 56,
      "side_effects": [
        "alopecia",
        "neutropenia"
      ],
      "patient_age": 66,
      "biomarkers": {
        "pd_l1_expression": "1_percent",
        "egfr_wild_type": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_009",
      "tumor_type": "lung_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 13.9,
      "initial_cell_count": 5550020,
      "drug_regimen": [
        "nivolumab"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 10.6,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 23.3,
      "time_to_response_days": 28,
      "side_effects": [
        "neutropenia",
        "nausea"
      ],
      "patient_age": 53,
      "biomarkers": {
        "pd_l1_expression": "1_percent",
        "egfr_wild_type": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_010",
      "tumor_type": "lung_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 20.5,
      "initial_cell_count": 8200118,
      "drug_regimen": [
        "pembrolizumab"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 16.5,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 19.3,
      "time_to_response_days": 14,
      "side_effects": [
        "thrombocytopenia",
        "nausea"
      ],
      "patient_age": 72,
      "biomarkers": {
        "pd_l1_expression": "1_percent",
        "egfr_wild_type": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_011",
      "tumor_type": "lung_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 13.0,
      "initial_cell_count": 5194091,
      "drug_regimen": [
        "osimertinib"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 5.7,
      "response_type": "partial_response",
      "tumor_reduction_percent": 56.4,
      "time_to_response_days": 84,
      "side_effects": [
        "thrombocytopenia",
        "nausea"
      ],
      "patient_age": 71,
      "biomarkers": {
        "pd_l1_expression": "1_percent",
        "egfr_wild_type": true
      }
    },
    {
      "trial_id": "LUNG_CANCER_012",
      "tumor_type": "lung_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 22.8,
      "initial_cell_count": 9104492,
      "drug_regimen": [
        "nivolumab"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 18.9,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 16.9,
      "time_to_response_days": 84,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 65,
      "biomarkers": {
        "kras_mutation": true,
        "alk_rearrangement": false
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_003",
      "tumor_type": "colorectal_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 7.1,
      "initial_cell_count": 2835382,
      "drug_regimen": [
        "5-fluorouracil",
        "leucovorin",
        "oxaliplatin"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 2.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 66.3,
      "time_to_response_days": 14,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 50,
      "biomarkers": {
        "kras_mutant": true,
        "braf_wild_type": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_004",
      "tumor_type": "colorectal_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 4.8,
      "initial_cell_count": 1901002,
      "drug_regimen": [
        "bevacizumab",
        "5-fluorouracil"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 3.3,
      "response_type": "partial_response",
      "tumor_reduction_percent": 31.0,
      "time_to_response_days": 56,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 61,
      "biomarkers": {
        "msi_high": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_005",
      "tumor_type": "colorectal_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 8.9,
      "initial_cell_count": 3550157,
      "drug_regimen": [
        "bevacizumab",
        "5-fluorouracil"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 5.0,
      "response_type": "partial_response",
      "tumor_reduction_percent": 43.6,
      "time_to_response_days": 56,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 60,
      "biomarkers": {
        "msi_high": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_006",
      "tumor_type": "colorectal_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 5.9,
      "initial_cell_count": 2366349,
      "drug_regimen": [
        "5-fluorouracil",
        "leucovorin",
        "oxaliplatin"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 2.6,
      "response_type": "partial_response",
      "tumor_reduction_percent": 56.7,
      "time_to_response_days": 28,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 70,
      "biomarkers": {
        "msi_high": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_007",
      "tumor_type": "colorectal_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 5.3,
      "initial_cell_count": 2108651,
      "drug_regimen": [
        "5-fluorouracil",
        "leucovorin",
        "oxaliplatin"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 4.3,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 18.7,
      "time_to_response_days": 56,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 59,
      "biomarkers": {
        "kras_wild_type": true,
        "msi_stable": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_008",
      "tumor_type": "colorectal_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 5.1,
      "initial_cell_count": 2040029,
      "drug_regimen": [
        "bevacizumab",
        "5-fluorouracil"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 3.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 39.5,
      "time_to_response_days": 21,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 51,
      "biomarkers": {
        "kras_wild_type": true,
        "msi_stable": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_009",
      "tumor_type": "colorectal_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 5.1,
      "initial_cell_count": 2051970,
      "drug_regimen": [
        "capecitabine"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 2.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 59.1,
      "time_to_response_days": 56,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 63,
      "biomarkers": {
        "kras_wild_type": true,
        "msi_stable": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_010",
      "tumor_type": "colorectal_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 10.0,
      "initial_cell_count": 3989675,
      "drug_regimen": [
        "irinotecan"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 5.0,
      "response_type": "partial_response",
      "tumor_reduction_percent": 49.6,
      "time_to_response_days": 42,
      "side_effects": [
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 65,
      "biomarkers": {
        "kras_wild_type": true,
        "msi_stable": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_011",
      "tumor_type": "colorectal_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 11.8,
      "initial_cell_count": 4725283,
      "drug_regimen": [
        "capecitabine"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 6.7,
      "response_type": "partial_response",
      "tumor_reduction_percent": 43.3,
      "time_to_response_days": 14,
      "side_effects": [
        "alopecia",
        "neutropenia"
      ],
      "patient_age": 59,
      "biomarkers": {
        "msi_high": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_012",
      "tumor_type": "colorectal_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 9.3,
      "initial_cell_count": 3736577,
      "drug_regimen": [
        "irinotecan"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 5.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 42.7,
      "time_to_response_days": 84,
      "side_effects": [
        "thrombocytopenia",
        "nausea"
      ],
      "patient_age": 57,
      "biomarkers": {
        "kras_mutant": true,
        "braf_wild_type": true
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_003",
      "tumor_type": "prostate_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 3.3,
      "initial_cell_count": 1325885,
      "drug_regimen": [
        "enzalutamide"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 1.6,
      "response_type": "partial_response",
      "tumor_reduction_percent": 52.1,
      "time_to_response_days": 42,
      "side_effects": [
        "thrombocytopenia",
        "nausea"
      ],
      "patient_age": 54,
      "biomarkers": {
        "psa_level": 35.8,
        "gleason_score": 7
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_004",
      "tumor_type": "prostate_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 2.3,
      "initial_cell_count": 926682,
      "drug_regimen": [
        "radium-223"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 1.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 51.8,
      "time_to_response_days": 42,
      "side_effects": [
        "alopecia",
        "neutropenia"
      ],
      "patient_age": 64,
      "biomarkers": {
        "psa_level": 35.8,
        "gleason_score": 7
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_005",
      "tumor_type": "prostate_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 3.6,
      "initial_cell_count": 1453595,
      "drug_regimen": [
        "docetaxel"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 2.6,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 29.7,
      "time_to_response_days": 21,
      "side_effects": [
        "neutropenia",
        "nausea"
      ],
      "patient_age": 59,
      "biomarkers": {
        "psa_level": 85.4,
        "gleason_score": 8
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_006",
      "tumor_type": "prostate_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 8.1,
      "initial_cell_count": 3239237,
      "drug_regimen": [
        "cabazitaxel"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 3.3,
      "response_type": "partial_response",
      "tumor_reduction_percent": 59.1,
      "time_to_response_days": 14,
      "side_effects": [
        "diarrhea",
        "nausea"
      ],
      "patient_age": 57,
      "biomarkers": {
        "psa_level": 35.8,
        "gleason_score": 7
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_007",
      "tumor_type": "prostate_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 8.1,
      "initial_cell_count": 3248911,
      "drug_regimen": [
        "radium-223"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 5.8,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 29.2,
      "time_to_response_days": 14,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 57,
      "biomarkers": {
        "psa_level": 85.4,
        "gleason_score": 8
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_008",
      "tumor_type": "prostate_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 7.6,
      "initial_cell_count": 3024321,
      "drug_regimen": [
        "docetaxel"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 5.0,
      "response_type": "partial_response",
      "tumor_reduction_percent": 33.6,
      "time_to_response_days": 21,
      "side_effects": [
        "diarrhea",
        "nausea"
      ],
      "patient_age": 74,
      "biomarkers": {
        "psa_level": 85.4,
        "gleason_score": 8
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_009",
      "tumor_type": "prostate_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 8.5,
      "initial_cell_count": 3415120,
      "drug_regimen": [
        "abiraterone"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 6.2,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 27.4,
      "time_to_response_days": 56,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 54,
      "biomarkers": {
        "psa_level": 35.8,
        "gleason_score": 7
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_010",
      "tumor_type": "prostate_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 6.0,
      "initial_cell_count": 2403133,
      "drug_regimen": [
        "docetaxel"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 3.8,
      "response_type": "partial_response",
      "tumor_reduction_percent": 36.9,
      "time_to_response_days": 28,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 58,
      "biomarkers": {
        "psa_level": 15.2,
        "gleason_score": 6
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_011",
      "tumor_type": "prostate_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 2.8,
      "initial_cell_count": 1118434,
      "drug_regimen": [
        "abiraterone"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 1.9,
      "response_type": "partial_response",
      "tumor_reduction_percent": 32.1,
      "time_to_response_days": 84,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 75,
      "biomarkers": {
        "psa_level": 85.4,
        "gleason_score": 8
      }
    },
    {
      "trial_id": "PROSTATE_CANCER_012",
      "tumor_type": "prostate_cancer",
      "stage": 1,
      "initial_tumor_volume_cm3": 3.2,
      "initial_cell_count": 1285519,
      "drug_regimen": [
        "radium-223"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 1.9,
      "response_type": "partial_response",
      "tumor_reduction_percent": 39.8,
      "time_to_response_days": 84,
      "side_effects": [
        "alopecia",
        "neutropenia"
      ],
      "patient_age": 56,
      "biomarkers": {
        "psa_level": 35.8,
        "gleason_score": 7
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_003",
      "tumor_type": "pancreatic_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 13.0,
      "initial_cell_count": 5217319,
      "drug_regimen": [
        "erlotinib",
        "gemcitabine"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 9.5,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 27.0,
      "time_to_response_days": 28,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 75,
      "biomarkers": {
        "ca19_9": 450,
        "tp53_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_004",
      "tumor_type": "pancreatic_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 9.1,
      "initial_cell_count": 3620544,
      "drug_regimen": [
        "5-fluorouracil",
        "leucovorin",
        "irinotecan",
        "oxaliplatin"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 5.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 40.5,
      "time_to_response_days": 56,
      "side_effects": [
        "alopecia",
        "neutropenia"
      ],
      "patient_age": 64,
      "biomarkers": {
        "ca19_9": 850,
        "kras_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_005",
      "tumor_type": "pancreatic_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 7.0,
      "initial_cell_count": 2816397,
      "drug_regimen": [
        "5-fluorouracil",
        "leucovorin",
        "irinotecan",
        "oxaliplatin"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 6.9,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 2.2,
      "time_to_response_days": 28,
      "side_effects": [
        "alopecia",
        "neutropenia"
      ],
      "patient_age": 58,
      "biomarkers": {
        "ca19_9": 850,
        "kras_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_006",
      "tumor_type": "pancreatic_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 4.8,
      "initial_cell_count": 1930872,
      "drug_regimen": [
        "erlotinib",
        "gemcitabine"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 3.5,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 27.0,
      "time_to_response_days": 28,
      "side_effects": [
        "rash",
        "diarrhea"
      ],
      "patient_age": 65,
      "biomarkers": {
        "ca19_9": 2200,
        "brca2_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_007",
      "tumor_type": "pancreatic_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 17.9,
      "initial_cell_count": 7164998,
      "drug_regimen": [
        "erlotinib",
        "gemcitabine"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 16.1,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 9.9,
      "time_to_response_days": 28,
      "side_effects": [
        "rash",
        "diarrhea"
      ],
      "patient_age": 52,
      "biomarkers": {
        "ca19_9": 450,
        "tp53_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_008",
      "tumor_type": "pancreatic_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 8.6,
      "initial_cell_count": 3457689,
      "drug_regimen": [
        "gemcitabine"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 6.4,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 26.0,
      "time_to_response_days": 28,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 62,
      "biomarkers": {
        "ca19_9": 450,
        "tp53_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_009",
      "tumor_type": "pancreatic_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 5.8,
      "initial_cell_count": 2334358,
      "drug_regimen": [
        "erlotinib",
        "gemcitabine"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 4.8,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 17.1,
      "time_to_response_days": 28,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 50,
      "biomarkers": {
        "ca19_9": 850,
        "kras_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_010",
      "tumor_type": "pancreatic_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 4.2,
      "initial_cell_count": 1672982,
      "drug_regimen": [
        "erlotinib",
        "gemcitabine"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 4.0,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 5.4,
      "time_to_response_days": 42,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 59,
      "biomarkers": {
        "ca19_9": 450,
        "tp53_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_011",
      "tumor_type": "pancreatic_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 15.9,
      "initial_cell_count": 6351485,
      "drug_regimen": [
        "erlotinib",
        "gemcitabine"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 13.9,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 12.5,
      "time_to_response_days": 84,
      "side_effects": [
        "neutropenia",
        "nausea"
      ],
      "patient_age": 56,
      "biomarkers": {
        "ca19_9": 450,
        "tp53_mutation": true
      }
    },
    {
      "trial_id": "PANCREATIC_CANCER_012",
      "tumor_type": "pancreatic_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 17.5,
      "initial_cell_count": 7014627,
      "drug_regimen": [
        "gemcitabine"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 14.3,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 18.2,
      "time_to_response_days": 21,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 46,
      "biomarkers": {
        "ca19_9": 450,
        "tp53_mutation": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_003",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 26.9,
      "initial_cell_count": 10779907,
      "drug_regimen": [
        "bevacizumab",
        "temozolomide"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 23.1,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 14.3,
      "time_to_response_days": 14,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 62,
      "biomarkers": {
        "mgmt_methylated": true,
        "idh1_wild_type": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_004",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 27.3,
      "initial_cell_count": 10925834,
      "drug_regimen": [
        "lomustine"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 27.2,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 0.5,
      "time_to_response_days": 84,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 70,
      "biomarkers": {
        "idh1_mutant": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_005",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 18.1,
      "initial_cell_count": 7242677,
      "drug_regimen": [
        "bevacizumab",
        "temozolomide"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 17.0,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 6.3,
      "time_to_response_days": 84,
      "side_effects": [
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 74,
      "biomarkers": {
        "idh1_mutant": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_006",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 14.4,
      "initial_cell_count": 5760369,
      "drug_regimen": [
        "carmustine"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 14.0,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 2.6,
      "time_to_response_days": 21,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 61,
      "biomarkers": {
        "mgmt_unmethylated": true,
        "egfr_amplification": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_007",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 31.4,
      "initial_cell_count": 12563558,
      "drug_regimen": [
        "bevacizumab",
        "temozolomide"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 27.3,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 13.0,
      "time_to_response_days": 56,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 53,
      "biomarkers": {
        "idh1_mutant": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_008",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 20.7,
      "initial_cell_count": 8297824,
      "drug_regimen": [
        "temozolomide"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 19.8,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 4.7,
      "time_to_response_days": 21,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 45,
      "biomarkers": {
        "idh1_mutant": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_009",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 27.4,
      "initial_cell_count": 10967598,
      "drug_regimen": [
        "lomustine"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 26.0,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 5.0,
      "time_to_response_days": 14,
      "side_effects": [
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 55,
      "biomarkers": {
        "mgmt_methylated": true,
        "idh1_wild_type": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_010",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 32.4,
      "initial_cell_count": 12976959,
      "drug_regimen": [
        "bevacizumab",
        "temozolomide"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 31.1,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 4.1,
      "time_to_response_days": 84,
      "side_effects": [
        "rash",
        "diarrhea"
      ],
      "patient_age": 62,
      "biomarkers": {
        "mgmt_unmethylated": true,
        "egfr_amplification": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_011",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 17.3,
      "initial_cell_count": 6938155,
      "drug_regimen": [
        "carmustine"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 15.2,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 12.4,
      "time_to_response_days": 14,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 54,
      "biomarkers": {
        "mgmt_methylated": true,
        "idh1_wild_type": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_012",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 13.1,
      "initial_cell_count": 5250988,
      "drug_regimen": [
        "bevacizumab",
        "temozolomide"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 12.5,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 5.1,
      "time_to_response_days": 21,
      "side_effects": [
        "rash",
        "diarrhea"
      ],
      "patient_age": 62,
      "biomarkers": {
        "mgmt_methylated": true,
        "idh1_wild_type": true
      }
    },
    {
      "trial_id": "MELANOMA_003",
      "tumor_type": "melanoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 9.0,
      "initial_cell_count": 3585667,
      "drug_regimen": [
        "vemurafenib"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 7.3,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 18.6,
      "time_to_response_days": 56,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 62,
      "biomarkers": {
        "braf_wild_type": true,
        "nras_mutation": true
      }
    },
    {
      "trial_id": "MELANOMA_004",
      "tumor_type": "melanoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 9.3,
      "initial_cell_count": 3720373,
      "drug_regimen": [
        "cobimetinib",
        "vemurafenib"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 2.8,
      "response_type": "partial_response",
      "tumor_reduction_percent": 70.3,
      "time_to_response_days": 42,
      "side_effects": [
        "alopecia",
        "neutropenia"
      ],
      "patient_age": 58,
      "biomarkers": {
        "braf_v600e_mutation": true,
        "nras_wild_type": true
      }
    },
    {
      "trial_id": "MELANOMA_005",
      "tumor_type": "melanoma",
      "stage": 2,
      "initial_tumor_volume_cm3": 9.9,
      "initial_cell_count": 3965096,
      "drug_regimen": [
        "pembrolizumab"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 3.3,
      "response_type": "partial_response",
      "tumor_reduction_percent": 66.3,
      "time_to_response_days": 56,
      "side_effects": [
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 69,
      "biomarkers": {
        "braf_v600e_mutation": true,
        "nras_wild_type": true
      }
    },
    {
      "trial_id": "MELANOMA_006",
      "tumor_type": "melanoma",
      "stage": 2,
      "initial_tumor_volume_cm3": 2.6,
      "initial_cell_count": 1026244,
      "drug_regimen": [
        "dabrafenib",
        "trametinib"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 1.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 44.4,
      "time_to_response_days": 28,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 56,
      "biomarkers": {
        "braf_v600e_mutation": true,
        "nras_wild_type": true
      }
    },
    {
      "trial_id": "MELANOMA_007",
      "tumor_type": "melanoma",
      "stage": 2,
      "initial_tumor_volume_cm3": 5.2,
      "initial_cell_count": 2074457,
      "drug_regimen": [
        "ipilimumab",
        "nivolumab"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 3.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 34.2,
      "time_to_response_days": 84,
      "side_effects": [
        "rash",
        "diarrhea"
      ],
      "patient_age": 60,
      "biomarkers": {
        "braf_wild_type": true,
        "nras_mutation": true
      }
    },
    {
      "trial_id": "MELANOMA_008",
      "tumor_type": "melanoma",
      "stage": 2,
      "initial_tumor_volume_cm3": 9.8,
      "initial_cell_count": 3902429,
      "drug_regimen": [
        "dabrafenib",
        "trametinib"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 4.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 54.5,
      "time_to_response_days": 42,
      "side_effects": [
        "alopecia",
        "neutropenia"
      ],
      "patient_age": 49,
      "biomarkers": {
        "pd_l1_positive": true,
        "braf_wild_type": true
      }
    },
    {
      "trial_id": "MELANOMA_009",
      "tumor_type": "melanoma",
      "stage": 2,
      "initial_tumor_volume_cm3": 5.4,
      "initial_cell_count": 2156704,
      "drug_regimen": [
        "pembrolizumab"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 3.7,
      "response_type": "partial_response",
      "tumor_reduction_percent": 32.1,
      "time_to_response_days": 42,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 56,
      "biomarkers": {
        "pd_l1_positive": true,
        "braf_wild_type": true
      }
    },
    {
      "trial_id": "MELANOMA_010",
      "tumor_type": "melanoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 3.1,
      "initial_cell_count": 1255901,
      "drug_regimen": [
        "ipilimumab",
        "nivolumab"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 2.2,
      "response_type": "partial_response",
      "tumor_reduction_percent": 31.0,
      "time_to_response_days": 84,
      "side_effects": [
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 68,
      "biomarkers": {
        "pd_l1_positive": true,
        "braf_wild_type": true
      }
    },
    {
      "trial_id": "MELANOMA_011",
      "tumor_type": "melanoma",
      "stage": 3,
      "initial_tumor_volume_cm3": 9.8,
      "initial_cell_count": 3930650,
      "drug_regimen": [
        "pembrolizumab"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 3.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 68.2,
      "time_to_response_days": 28,
      "side_effects": [
        "diarrhea",
        "nausea"
      ],
      "patient_age": 72,
      "biomarkers": {
        "braf_wild_type": true,
        "nras_mutation": true
      }
    },
    {
      "trial_id": "MELANOMA_012",
      "tumor_type": "melanoma",
      "stage": 3,
      "initial_tumor_volume_cm3": 7.9,
      "initial_cell_count": 3141595,
      "drug_regimen": [
        "vemurafenib"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 2.8,
      "response_type": "partial_response",
      "tumor_reduction_percent": 64.3,
      "time_to_response_days": 56,
      "side_effects": [
        "rash",
        "diarrhea"
      ],
      "patient_age": 50,
      "biomarkers": {
        "braf_wild_type": true,
        "nras_mutation": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_003",
      "tumor_type": "ovarian_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 7.2,
      "initial_cell_count": 2881110,
      "drug_regimen": [
        "carboplatin",
        "paclitaxel"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 3.7,
      "response_type": "partial_response",
      "tumor_reduction_percent": 48.1,
      "time_to_response_days": 42,
      "side_effects": [
        "neutropenia",
        "nausea"
      ],
      "patient_age": 52,
      "biomarkers": {
        "ca125": 850,
        "brca2_mutation": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_004",
      "tumor_type": "ovarian_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 15.7,
      "initial_cell_count": 6278894,
      "drug_regimen": [
        "doxorubicin",
        "carboplatin"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 5.6,
      "response_type": "partial_response",
      "tumor_reduction_percent": 64.5,
      "time_to_response_days": 42,
      "side_effects": [
        "thrombocytopenia",
        "nausea"
      ],
      "patient_age": 73,
      "biomarkers": {
        "ca125": 180,
        "brca_wild_type": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_005",
      "tumor_type": "ovarian_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 7.5,
      "initial_cell_count": 3019035,
      "drug_regimen": [
        "bevacizumab",
        "carboplatin",
        "paclitaxel"
      ],
      "treatment_duration_days": 168,
      "final_tumor_volume_cm3": 3.1,
      "response_type": "partial_response",
      "tumor_reduction_percent": 59.1,
      "time_to_response_days": 14,
      "side_effects": [
        "hypertension",
        "proteinuria"
      ],
      "patient_age": 60,
      "biomarkers": {
        "ca125": 420,
        "brca1_mutation": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_006",
      "tumor_type": "ovarian_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 5.1,
      "initial_cell_count": 2036606,
      "drug_regimen": [
        "niraparib"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 2.0,
      "response_type": "partial_response",
      "tumor_reduction_percent": 59.9,
      "time_to_response_days": 84,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 66,
      "biomarkers": {
        "ca125": 420,
        "brca1_mutation": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_007",
      "tumor_type": "ovarian_cancer",
      "stage": 2,
      "initial_tumor_volume_cm3": 8.6,
      "initial_cell_count": 3425237,
      "drug_regimen": [
        "doxorubicin",
        "carboplatin"
      ],
      "treatment_duration_days": 126,
      "final_tumor_volume_cm3": 4.6,
      "response_type": "partial_response",
      "tumor_reduction_percent": 46.4,
      "time_to_response_days": 28,
      "side_effects": [
        "peripheral_neuropathy",
        "fatigue"
      ],
      "patient_age": 64,
      "biomarkers": {
        "ca125": 180,
        "brca_wild_type": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_008",
      "tumor_type": "ovarian_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 5.2,
      "initial_cell_count": 2073612,
      "drug_regimen": [
        "bevacizumab",
        "carboplatin",
        "paclitaxel"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 4.3,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 16.1,
      "time_to_response_days": 84,
      "side_effects": [
        "thrombocytopenia",
        "nausea"
      ],
      "patient_age": 58,
      "biomarkers": {
        "ca125": 420,
        "brca1_mutation": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_009",
      "tumor_type": "ovarian_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 16.5,
      "initial_cell_count": 6603262,
      "drug_regimen": [
        "niraparib"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 6.7,
      "response_type": "partial_response",
      "tumor_reduction_percent": 59.6,
      "time_to_response_days": 28,
      "side_effects": [
        "hand_foot_syndrome",
        "diarrhea"
      ],
      "patient_age": 69,
      "biomarkers": {
        "ca125": 420,
        "brca1_mutation": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_010",
      "tumor_type": "ovarian_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 12.6,
      "initial_cell_count": 5058168,
      "drug_regimen": [
        "doxorubicin",
        "carboplatin"
      ],
      "treatment_duration_days": 63,
      "final_tumor_volume_cm3": 8.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 33.2,
      "time_to_response_days": 56,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 55,
      "biomarkers": {
        "ca125": 180,
        "brca_wild_type": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_011",
      "tumor_type": "ovarian_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 14.5,
      "initial_cell_count": 5819317,
      "drug_regimen": [
        "olaparib"
      ],
      "treatment_duration_days": 84,
      "final_tumor_volume_cm3": 7.2,
      "response_type": "partial_response",
      "tumor_reduction_percent": 50.2,
      "time_to_response_days": 14,
      "side_effects": [
        "diarrhea",
        "nausea"
      ],
      "patient_age": 50,
      "biomarkers": {
        "ca125": 180,
        "brca_wild_type": true
      }
    },
    {
      "trial_id": "OVARIAN_CANCER_012",
      "tumor_type": "ovarian_cancer",
      "stage": 4,
      "initial_tumor_volume_cm3": 11.1,
      "initial_cell_count": 4432175,
      "drug_regimen": [
        "olaparib"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 7.4,
      "response_type": "partial_response",
      "tumor_reduction_percent": 33.0,
      "time_to_response_days": 28,
      "side_effects": [
        "fatigue",
        "anemia"
      ],
      "patient_age": 48,
      "biomarkers": {
        "ca125": 420,
        "brca1_mutation": true
      }
    },
    {
      "trial_id": "GLIOBLASTOMA_013",
      "tumor_type": "glioblastoma",
      "stage": 4,
      "initial_tumor_volume_cm3": 17.5,
      "initial_cell_count": 6993871,
      "drug_regimen": [
        "lomustine"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 16.1,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 7.7,
      "time_to_response_days": 28,
      "side_effects": [
        "thrombocytopenia",
        "nausea"
      ],
      "patient_age": 61,
      "biomarkers": {
        "idh1_mutant": true
      }
    },
    {
      "trial_id": "COLORECTAL_CANCER_013",
      "tumor_type": "colorectal_cancer",
      "stage": 3,
      "initial_tumor_volume_cm3": 5.3,
      "initial_cell_count": 2110652,
      "drug_regimen": [
        "irinotecan"
      ],
      "treatment_duration_days": 180,
      "final_tumor_volume_cm3": 2.7,
      "response_type": "partial_response",
      "tumor_reduction_percent": 48.7,
      "time_to_response_days": 21,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 58,
      "biomarkers": {
        "kras_mutant": true,
        "braf_wild_type": true
      }
    },
    {
      "trial_id": "MELANOMA_013",
      "tumor_type": "melanoma",
      "stage": 3,
      "initial_tumor_volume_cm3": 6.1,
      "initial_cell_count": 2433789,
      "drug_regimen": [
        "pembrolizumab"
      ],
      "treatment_duration_days": 42,
      "final_tumor_volume_cm3": 4.6,
      "response_type": "stable_disease",
      "tumor_reduction_percent": 24.2,
      "time_to_response_days": 28,
      "side_effects": [
        "arthralgia",
        "fatigue"
      ],
      "patient_age": 55,
      "biomarkers": {
        "braf_wild_type": true,
        "nras_mutation": true
      }
    }
  ]
}